UNITÉ DE RECHERCHE INSERM UMR S 911 Centre de Recherche en Oncologie Biologique et Oncopharmacologie

Transcription

1 UNITÉ DE RECHERCHE INSERM UMR S 911 Centre de Recherche en Oncologie Biologique et Oncopharmacologie (CRO2) DIRECTEUR : LOMBARDO Dominique ADRESSE : Faculté de Médecine Site Timone TELEPHONE : /02 COURRIEL : dominique.lombardo@univ-amu.fr SITE WEB : ECOLE DOCTORALE : Sciences de la Vie et de la Santé (ED 062) RATTACHEMENTS : AMU INSERM POLES HOSPITALIERS : 3 - Imagerie Médicale (Intersites) 5 - Anapath-Digestif-Onco-Uro-Endocrinologie (Nord) 6 - Neurosciences Cliniques (Intersites) 13 - Pédiatrie Médico-Chirurgicale (Intersites) 16 - Cardio-Vasculaire-Thoracique (Intersites) 18 - biologie (Intersites) 24 - Pharmacie 26 - MINC SMC (Intersites) 28 - DACCORD (Intersites) DISCIPLINES D APPARTENANCES : DS 5 - Biologie, médecine, santé SPECIALITÉS : Oncologie/Immunologie/Neuroncologie/Pharmacologie GESTIONNAIRES UNITÉ : Laurent NOE 1/17

2 Enseignants-Chercheurs : 54 Chercheurs EPST : 4 Autres Enseignants-Chercheurs et Chercheurs : 7 BIATSS/ITA : 45 Autres BIATSS/ITA : 4 Doctorants : 31 EFFECTIFS PERSONNELS IMPLIQUÉS DANS RECHERCHE AIT BELKACEM Rima E ALCARAZ Sonia ALLEGRO Diane ASI AMU ANDRE Frédéric ANDRE Marc TCH INSERM ANDRE Nicolas ANDREI Roman (Co-tutelle) BAEZA Nathalie IGE AMU BARBIER Pascale BANEYX Guillaume BARBOLOSI Dominique BAREA Dolores TCH AMU BARKULOVA Ayuna E BARLESI Fabrice BASTIDE Cyrille BASTONERO Sonia IE AMU BELOROBI Sadia BENAY Stephan BENYAHIA Zohra BERAUD Evelyne BERGES Raphael POST BERNARD Jean-Paul BERTHOIS Yolande CR INSERM BONIER Rénaté AJT INSERM BOUDOURESQUE Françoise BOURGAREL-REY Véronique BOUVET Sandrine ADA AMU BOUVIER-LABIT Corinne BRAGUER Diane BREUZARD Gilles BRUN Nadia CAMMILLERI Serge CAPRIOLO Guy CARLIER Anne-Sophie CARMONA Sylvie TCH AMU CARRE Manon CAYOL Mylène CHACON Christine ASI AMU CHERRAFT Rachida CHINOT Olivier CHOCRY Mathieu CICCOLINI Joseph -PA COLIGNON Aurélie IG (CDD, Ft7) /17

3 COLIN Carole IGR AMU COLOMB Coline CONTE Philippe AJT INSERM CORREARD Florian CRENON-CONSTARATAS Isabelle DAHAN Laetitia DAIZE Caroline IGE AMU DANIEL Laurent DARDAR Zoubeir DEBESSA Tiffany (Co-tutelle) DELFINO Christine IGR AMU DENICOLAI Emilie DEVRED François DUSSAULT Nadège ASI AMU DUSSERT Christophe CR INSERM EL BATTARI Assou ESTEVE Marie-Anne DOUILLARD Soazig IE AMU FAIVRE Christian FANCIULLINO Raphaelle FIGARELLA-BRANGER Dominique GAGNA Véronique GARROUSTE Françoise GAUDY Caroline GERMAIN Sébastien TCH AMU GEROLAMI René GIACOMETTI Sarah TCN AMU GIORDANENGO Audrey E GROB Jean-Jacques HEURTE Delphine E HONORE Stéphane ILIADIS Athanassios INTAGLIATA Dominique TCH AMU JIGUET-JIGLAIRE Carine POST KHELOUFI Farid KOVACIC Hervé LACARELLE Bruno LAFITTE Daniel IGR AMU LEGRAND Marion LELOUP Ludovic LEMOINE Lenaig ITA CT C contractuel AMU LOMBARDO Dominique DR INSERM LUIS José MALESINSKI Soazig IE AMU MAROUANI Hafedh MARTINEZ Emmanuelle MARTYROSIAN Anna POST- MARVALDI Jacques MAS Eric DR INSERM MATHIEU Sylvie IE INSERM McKAY Nathalie TCN contractuel MERCIER Cédric PH METELLUS Philippe MERCURIO Sandy MOHAMED Echata MOLLARD Severine POST- MONJANEL-MOUTERDE Suzanne MONTERO Marie-Pierre MORANDO Philippe TCH AMU MOUSSLIM Mohamed NDYAYE Sega POST NEANT Nadège NOE Laurent IGE AMU NOUAR Roqya NOUGUEREDE Emilie IGR (AP-HM) 3/17

4 OUAFIK L'Houcine OUAISSI Mehdi PADOVANI Laetitia PAGANO Alessandra PARAT Fabrice TCH AMU PELLEGRINO Emilie PERROQUIN Gladys TCH INSERM PETIT Marie PEYROT Vincent PIRISI Victor TCH INSERM POMMIER Gilbert PREVOT Charles IR CNRS RAUJOL Julie E RICHARD Marie Aleth RIGOT-ANDRE Véronique SALAS Sébastien PH SASTRE Bernard SBARRA Véronique AI INSERM SCHEMBRI Thérèse IGE AMU SEBBAN Sylvie TCN-CDD INSERM SEITZ Jean-François SELLANI Lina POST SERDJEBI Cindy SIGAUD Romain Master 2 R SILVY Françoise TCH INSERM SIRET Carole IGE AMU SCHMIDT Guillaume TCN CDD (AP-HM) SOLAS-CHESNEAU Caroline TAYA Sarah TCH INSERM TERCIOLO Chloé THUAUT Sylvie TIJERAS Guylaine TOMASINI Pascale TOUNSI Asma TSVETKOV Philipp POST VILLARD Claude IE CNRS WOLOCH Christian PERSONNELS AVEC HDR ANDRE Frédéric ANDRE Nicolas BARBOLOSI Dominique BARLESI Fabrice BASTIDE Cyrille BERAUD Evelyne BERNARD Jean-Paul BOUDOURESQUE Françoise BOURGAREL-REY Véronique BOUVIER-LABIT Corinne BRAGUER Diane CHINOT Olivier CICCOLINI Joseph DANIEL Laurent DUSSERT Christophe EL BATTARI Assou FAIVRE Christian FIGARELLA-BRANGER Dominique GEROLAMI René GROB Jean-Jacques HONORE Stéphane ILIADIS Athanassios MCU-PA CR INSERM 4/17

5 KOVACIC Hervé LACARELLE Bruno LAFITTE Daniel LOMBARDO Dominique LUIS José MARVALDI Jacques MAS Eric METELLUS Philippe MONJANEL-MOUTERDE Suzanne OUAFIK L'Houcine OUAISSI Mehdi PEYROT Vincent POMMIER Gilbert RICHARD Marie Aleth SALAS Sébastien SASTRE Bernard SEITZ Jean-François IGR AMU DR INSERM DR INSERM PH EQUIPES DE RECHERCHE et THEMATIQUES EQUIPE : E1 - Communications microtubules-mitochondries : implication en oncopharmacologie RESPONSABLE : BRAGUER Diane THEMATIQUE : Dialogue microtubules mitochondries et conséquences fonctionnelles. Dépendance à la chimiothérapie et perspectives thérapeutiques EQUIPE : E2 - Micro-environnement Redox, cytosquelette et progression tumorale RESPONSABLE : KOVACIC Hervé/PEYROT Vincent THEMATIQUE : Nox1, progression et migration tumorale. Potentialité thérapeutique et pronostique de la modulation redox en cancérologie EQUIPE : E3 - Progression tumorale et immunothérapie expérimentale RESPONSABLE : LOMBARDO Dominique BERNARD Jean-Paul THEMATIQUE : Immunothérapie expérimentale des adénocarcinomes pancréatiques. Cancer et thrombose. Molécules d'adhésion et carcinogénèse pancréatique EQUIPE : E4 - Angiogenèse, invasivité et micro-environnement tumoral RESPONSABLE : OUAFIK L'Houcine/FIGARELLA-BRANGER Dominique THEMATIQUE : Propriétés intrinsèques et micro-environnement dans le mode de croissance des glioblastomes. Rôle et mécanismes d'action de l'adrénoméduline dans la progression tumorale EQUIPE : SC - Service Commun RESPONSABLE : Laurent NOE Plateforme Pharmacocinétique et modélisation mathématique : SMARTc (AP-HM, Accréditation COFRAC) RESPONSABLE : LACARELLE Bruno Plateforme Protéomique et Innovation Technologique Timone : PIT2 (labellisation IBISa MaP) RESPONSABLE : LAFITTE Daniel Plateforme Laboratoire de transfert (AP-HM, Accréditation COFRAC) RESPONSABLE : L H OUAFIK. Plateforme Ressources Biologique Tumorothèque (AP-HM, Certification ISO 9001) RESPONSABLE : D. FIGARELLA-BRANGER Plateau Tri cellulaire RESPONSABLE : PREVOT Charles Plateau Imagerie confocale et intravitale RESPONSABLE : BASTONERO Sonia 5/17

6 PERSONNELS PAR EQUIPE DE RECHERCHE EQUIPE : E1 - Communications microtubules-mitochondries : implication en oncopharmacologie RESPONSABLE : BRAGUER Diane THEMATIQUE : Dialogue microtubules mitochondries et conséquences fonctionnelles. Dépendance à la chimiothérapie et perspectives thérapeutiques ANDRE Nicolas BARKULOVA Ayna BERGES Raphael BOURGAREL-REY Véronique BRAGUER Diane CARLIER Anne-Sophie CARRE Manon CHACON Christine CORREARD Florian ESTEVE Marie-Anne HONORE Stéphane LEGRAND Marion McKAY Nathalie MONTERO Marie-Pierre PETIT Marie TAYA Sarah POST- CDD ASI AMU TCN CDD TCH INSERM EQUIPE : E2 - Micro-environnement Redox, cytosquelette et progression tumorale RESPONSABLE : KOVACIC Hervé/PEYROT Vincent THEMATIQUE : NADPH oxydase, Cytosquelette, microtubules, progression et migration tumorale. ANDRE Marc TCH INSERM (en disponibilité, non remplacé) ANDREI ROMAN ALLEGRO Diane ASI AMU BARBIER Pascale MCU BOUVET Sandrine ADA AMU (40%) BREUZARD Gilles MCU CHERRAFT Rachida CHOCRY Mathieu DEBESSA Tiffany DEVRED François MCU GARROUSTE Françoise MCU HEURTE Delphine KOVACIC Hervé LELOUP Ludovic MCU LUIS José MACCARIO Hélène ATER MALESINSKI Soazig IE AMU (60%) MONJANEL-MOUTERDE Suzanne MCU MOUSSLIM Mohamed PAGANO Alessandra MCU PARAT Fabrice TCH AMU PEYROT Vincent POMMIER Gilbert (retraite, poste non remplacé) THUAUT Sylvie MCU (en partance) TSVETKOV Philipp POST- EQUIPE : E3 - Progression tumorale et immunothérapie expérimentale RESPONSABLE : LOMBARDO Dominique BERNARD Jean-Paul THEMATIQUE : Immunothérapie expérimentale des adénocarcinomes pancréatiques. Cancer et thrombose. Molécules d'adhésion et carcinogénèse pancréatique ANDRE Frédéric BAREA Dolores BELOROBI Sadia TCH AMU 6/17

7 BERAUD Evelyne BERNARD Jean-Paul BERTHOIS Yolande BOUDOURESQUE Françoise CAMMELIRI Serge CARMONA Sylvie COLIGNON Aurélie CRENON-CONSTARATAS Isabelle GEROLAMI René GERMAIN Sébastien LOMBARDO Dominique MARTINEZ Emmanuelle MARTYROSIAN Anna MAS Eric NOUGUEREDE Emilie OUAISSI Mehdi PERROQUIN Gladys RIGOT-ANDRE Véronique SASTRE Bernard SBARRA Véronique SCHMIDT Guillaume SILVY Françoise SIRET Carole TERCIOLO Chloé CR INSERM TCH AMU POST- TCH AMU DR INSERM POST- DR INSERM IGR AP-HM TCN INSERM AI INSERM TCN CDD (AP-HM) TCH INSERM IGE AMU EQUIPE : E4 - Angiogenèse, invasivité et micro-environnement tumoral RESPONSABLE : OUAFIK L'Houcine/FIGARELLA-BRANGER Dominique THEMATIQUE : Propriétés intrinsèques et micro-environnement dans le mode de croissance des glioblastomes. Rôle et mécanismes d'action de l'adrénoméduline dans la progression tumorale BAEZA-KALLEE Nathalie BAKAR Lenaig BARLESI Fabrice BASTIDE Cyrille BENYAHIA Zohra BOUVIER-LABIT Corinne CAYOL Mylène CHINOT Olivier COLIN Carole DAIZE Caroline DANIEL Laurent DARDAR Zoubeir DELFINO Christine DENICOLAI Emilie DUSSAULT Nadège EL BATTARI Assou FIGARELLA-BRANGER Dominique GAGNA Véronique GAUDY Caroline GROB Jean-Jacques INTAGLIATA Dominique JIGUET-JIGLAIRE Carine MATTEI Jean-Camille MATHIEU Sylvie METELLUS Philippe MORANDO Philippe OUAFIK L'Houcine RICHARD Marie Aleth SALAS Sébastien SIGAUD Romain SOUBERAN AURELIE TABOURET Emeline TCHOGHANDJIAN AURELIE IGE AMU IGR AMU IGE AMU IGR AMU ASI AMU TCH AMU POST- IE INSERM TCH AMU PH CDD AP-HM 7/17

8 TIJERAS-PICUS Guylaine TOMASINI Pascale TOUNSI Asma Plateforme Pharmacologie et Modélisation mathématique SMARTc (AP-HM, Accréditation COFRAC) RESPONSABLE : LACARELLE Bruno BARBOLOSI Dominique BENAY Stephan BANEYX Guillaume CICCOLINI Joseph FAIVRE Christian FANCIULINO Raphaëlle GIACOMETTI Sarah ILIADIS Athanassios KHELOUFI Farid LACARELLE Bruno LAUNAY Manon MERCIER Cédric NEANT Nadège SERDJEBI Cindy SOLAS-CHESNEAU Caroline WOLOCH Christian MCU-PA TCN AMU PH Plateforme Protéomique et Innovation Technologique Timone (PIT2, labellisation IBISa) RESPONSABLE : LAFITTE Daniel AIT BELKACEM Rima LAFITTE Daniel RAUJOL JULIE SCHEMBRI Thérèse VILLARD Claude E IGR AMU E IGE AMU IR CNRS Plateforme Laboratoire de transfert (AP-HM, Accréditation COFRAC) RESPONSABLE : L H OUAFIK. Plateforme Ressources Biologique Tumorothèque (AP-HM, Certification ISO 9001) RESPONSABLE : D. FIGARELLA-BRANGER Plateau Tri cellulaire RESPONSABLE : PREVOT Charles Plateau Imagerie confocale et intravitale RESPONSABLE : BASTONERO Sonia EQUIPE : SC - Service Commun Recherche RESPONSABLE : NOE Laurent ALCARAZ Sonia BONIER Rénaté BOUVET Sandrine CARLIER Anne-Sophie CAPRIOLO Guy CONTE Philippe GAGNA Véronique NOE Laurent MOHAMED Echata PERROQUIN Gladys AJT INSERM ADA AMU CDD AJT INSERM IGE AMU TCN INSERM 8/17

9 ACCUEIL MASTERS Génétique et Biologie de la Cellule-Université Claude Bernard Lyon I Métabolisme, endocrinologie, nutrition - Université Claude Bernard Lyon I Biomathématiques - Université Paris Vi Endocrinologie moléculaire et cellulaire - Université de Montpellier Bioinformatique Biologie structurale et génomique - Aix-Marseille Développement et Immunologie - Aix-Marseille Pathologie Humaine - Oncologie : pharmacologie et thérapeutique - Aix-Marseille Pathologie Humaine : Génomique et Santé - Aix-Marseille Nutrition - Sécurité Alimentaire - Aix-Marseille Chimie Environnementale - Aix-Marseille Pharmacocinétique Aix-Marseille EQUIPEMENTS MAJEURS 1/ Microscope électronique à transmission 2/ Systèmes d'imagerie infrarouge, luminescence et fluorescence (Pearl Li-Cor Société Sciencetec - Caliper Bio Imager 3 D) 3/ Imager MALDI TOF-TOF E21 (Plateforme protéomique) 4/ Microscope confocal 5/ Microscope intravital 6/ Vidéomicroscopes THESES DE DOCTORAT ANNÉE 2013 Mercurio Sandy : «Mise en évidence de nouvelles cibles thérapeutiques dans les tumeurs Gliales et glioneuronales de l enfant» 19 décembre 2013 Equipe 1 : SIRIC Lasernanobio ANR Contrat industriel Basilea En cours. Equipe 2 : SIRIC CONTRATS ANNÉE 2013 Equipe 3 : F. André (PI) Effet de S.Boulardii sur les molécules d adhérence. Implication dans le traitement des MICI. Biocodex En cours. E. Mas European grant (7th PCR : EndoTOFPET-US - Novel multimodal endoscopic probes for simultaneous PET/ultrasound imaging for image-guided interventions. (Grant no : ). En cours E. Mas : Grant «Research Collaboration and Option Agreement», Roche Glycart Biotechnology AG (F. Hoffman-la Roche Ltd), MATWIN, ValorPACA (Aix-Marseille Université) et INSERM Transfert en cours : Therapeutic antibodies, Diagnosis and Imaging of PDAC. D.Lombardo. Coordinateur Programme de recherche «Cancer du Pancréas» dans le cadre du SIRIC (Groupement de Coopération sanitaire Pôle Régional de référence en Cancérologie de PACA Ouest) Coordonateur : Pr P. Viens INCA /17

10 Equipe 4 : D.Figarella-Branger Coordinateur pour le site Marseille Centre de référence sur les tumeurs oligodendrogliales de haut grade (POLA) Coordinateur Pr JY. Delatre INCA/DHOS AAP centre de référence des cancers de l'adulte D.Figarella-Branger Investigateur. Sensitivity of resistance of CD8 anti-tumor T lymphocytes to mechasnisms of immunosuppression: relevance for human and mouse inflammatory melanomas ARC D.Figarella-Branger Investigateur Base clinico-biologique mélanome (BCB11-007) INCA D.Figarella-Branger Coordinateur associé Base clinico-biologique glioblastome (BCB12-012) INCA D.Figarella-Branger Investigateur Base clinico-biologique pancrés (BCB12-008) INCA D.Figarella-Branger Investigateur Base clinico-biologique sarcomes et tissus conjonctifs BCB12-005) INCA D.Figarella-Branger Coordinateur. Histopathologie expérimentale. INCa/Cancéropôle PACA D.Figarella-Branger Investigateur Projet interaxe : imagerie intravitale et Maldi pour le glioblastomes Coordinateur : G. Rougon INCa/Cancéropôle PACA D.Figarella-Branger.coordonateur associé Centre de référence pour les TUmeurs CErébrales RAres de l adulte (TUCERA) INCA D.Figarella-Branger investigateur Double lecture en neurooncologie pédiatrique Coordonateur national : Dr A. Jouvet INCA D.Figarella-Branger Coordinateur Programme de recherche gliome dans le cadre du SIRIC (Groupement de Coopération sanitaire Pôle Régional de référence en Cancérologie de PACA Ouest) Coordonateur : Pr P. Viens INCA C. Bouvier Relecteur Etude biologique thérapeutique REGOBONE-SARCOME 12-UC-0150/1309 INCA 2013-En cours Plateforme SMARTC Iliadis «sous CTA» Contrat Galderma Ciccolini - «Pharmacocinétique du bévacizumab» Subvention Cancéropôle 2013 Ciccolini - Recherche des effets séquernces anti-angiogéniques/cytotoxiques» Contrat Roche 2013 Ciccolini - «Développement des ANC»Subvention Gefluc 2013 Ciccolini «Essai du rhenium dans les modèles de cancer du sein» Subvention La Marie-Do 2014 Barlési-Barbolosi-Ciccolini «MARS Project» AMIDEX 2014 André-Ciccolini «MetroGem» Subvention Gefluc 2014 Plateforme PIT2 ANR PRADOX IAPP EuroMALDI /17

11 BREVETS ANNÉE 2013 Titre du Brevet Method for assessing the ability of a patient to respond to or be safely treated by a nucleoside analog based-chemotherapy Inventeurs : Ciccolini, Mercier, Dahan, Iliadis, Seitz, Ouafik N de dépôt : US A1 Année de dépôt : 2009 Année de publication : 10 janvier 2013 Déposant (Université de Méditerranée ) AMU Co-déposant (Inserm, AP..) : AP-HM Equipe 1 : BLICATIONS ANNÉE 2013 Rovini A, Gauthier G, Bergès R, Kruczynski A, Braguer D, Honoré S Anti-Migratory Effect of Vinflunine in Endothelial and Glioblastoma Cells Is Associated with Changes in EB1 C-Terminal Detyrosinated/Tyrosinated Status. PLoS One Jun 4;8(6) - (2013) Savry A, Carre M, Berges R, Rovini A, Pobel I, Chacon C, Braguer D, Bourgarel-Rey V Bcl-2- enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment.neoplasia Jan;15(1): (2013) Molina A, Velot L, Ghouinem L, Abdelkarim M, Bouchet BP, Luissint AC, Bouhlel I, Morel M, Sapharikas E, di Tommaso A, Honore S, Braguer D, Gruel N, Vincent-Salomon A, Delattre O, Sigal- Zafrani B, Andre F, Terris B, Akhmanova A, Di Benedetto M, Nahmias C ATIP3, a novel prognostic marker of breast cancer patient survival, limits cancer cell migration and slows metastatic progression by regulating microtubule dynamics. Cancer Res Feb 8. - (2013) Mercurio S, Padovani L, Colin C, Carré M, Tchoghandjian A, Scavarda D, Lambert S, Baeza-Kallee N, Fernandez C, Chappé C, André N, Figarella-Branger D Evidence for new targets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma Acta Neuropathologica Communications :7 - (2013) André N, Banavali S, Snihur Y, Pasquier E Has the time come for metronomics in low-income and middle-income countries? Lancet Oncol May;14(6):e (2013) Pasquier E, Street J, Pouchy C, Carre M, Gifford AJ, Murray J, Norris MD, Trahair T, Andre N, Kavallaris M β-blockers increase response to chemotherapy via direct antitumour and antiangiogenic mechanisms in neuroblastoma.br J Cancer May 21. doi: /bjc (2013) Pasquier E, Tuset MP, Street J, Sinnappan S, MacKenzie KL, Braguer D, Andre N, Kavallaris M Concentration- and schedule-dependent effects of chemotherapy on the angiogenic potential and drug sensitivity of vascular endothelial cells.angiogenesis Apr;16(2): (2013) Chappé C, Riffaud L, Tréguier C, Carsin-Nicol B, Veillard D, Chiforeanu DC, Grill J, Frappaz D, André N, Millot F, Vinchon M, Sirvent N, Edan C.Primary gliomatosis cerebri involving gray matter in pediatrics: a distinct entity? A multicenter study of 14 cases.childs Nerv Syst Jan (2013) Faivre C, Barbolosi D, Pasquier E, André N.A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens.cancer Chemother Pharmacol Feb 7. - (2013). 11/17

12 Equipe 2 : Deciphering the molecular mechanisms of anti-tubulin plant derived drugs P. Barbier, P. O. Tsvetkov, G. Breuzard, F. Devred PHYTOCHEMISTRY REVIEWS Volume: 13 Issue: 1 Special Issue: SI Pages: PIVL, a new serine protease inhibitor from Macrovipera lebetina transmediterranea venom, impairs motility of human glioblastoma cells. Morjen M., Kallech-ziri O., Bazaa A., Othman H., Mabrouk K., Zouari-Kessentini R., Sanz L., Calvete J.J, Srairi-Abid N., El Ayeb M., Luis J. & Marrakchi N. Matrix Biol. 32, (2013) Antitumoral Potential of Tunisian Snake Venoms Secreted Phospholipases A2. Zouari-Kessentini R., Srairi-Abid N., Bazaa A., El Ayeb M., Luis J. & Marrakchi N. BioMed Research International 2013, 9. Snake venom peptides: promising molecules with anti-tumor effects. Sarray S., Luis J., El Ayeb M. and Marrakchi N. - In Bioactive food peptides in health and disease (ISBN ). InTech - Open Access Publisher (Hernández-Ledesma, B.; Hsieh, C.C., eds.) pp (2013) Biochemical and structural studies of the oligomerization domain of the Nipah virus phosphoprotein: Evidence for an elongated coiled-coil homotrimer. David Blocquel, Matilde Beltrandi, Jenny Erales,Pascale Barbier,Sonia Longhi. Virology, Volume 446, Issues 1 2, November 2013, Pages Microtubule-associated proteins and tubulin interaction by isothermal titration calorimetry. Tsvetkov PO, Barbier P, Breuzard G, Peyrot V, Devred F. Methods Cell Biol. 2013;115: (2013) Molecular Mechanisms of Tau Binding to Microtubule and its Role in Microtubule Dynamics in Live Cells. Breuzard G, Hubert P, Nouar R, De Bessa T, Devred F, Barbier P, Sturgis JN, Peyrot V. J Cell Sci Jul 1;126(Pt 13): FRET and FRAP imaging: approaches to characterize tau and stathmin interactions with microtubules in cells. Nouar R, Devred F, Breuzard G, Peyrot V. Biol Cell Apr;105(4): Expression of a functional recombinant C-type lectin-like protein lebecetin in the human embryonic kidney cells. Jebali J, Jeanneau C, Morjen M, Mathieu S, Bazaa A, El Ayeb M, Luis J, Gargouri A, Marrakchi N, el Battari A. Biotechnol Prog Nov-Dec;28(6): PIVL, a new serine protease inhibitor from Macrovipera lebetina transmediterranea venom, impairs motility of human glioblastoma cells. Morjen M, Kallech-Ziri O, Bazaa A, Othman H, Mabrouk K, Zouari-Kessentini R, Sanz L, Calvete JJ, Srairi-Abid N, El Ayeb M, Luis J, Marrakchi N. Matrix Biol Dec 20. Equipe 3 : Fontbonne H, Puigserver A, Bouza B, Lombardo D, Ajandouz el H. Activation of bile salt dependent lipase by (lyso)phosphatidic acid and platelet activating factor. FEBS Lett Sep 17;587(18): Silvy F, Lissitzky JC, Bruneau N, Zucchini N, Landrier JF, Lombardo D, Verrando P. Resistance to cisplatin-induced cell death conferred by the activity of organic anion transporting polypeptides (OATP) in human melanoma cells. Pigment Cell Melanoma Res Jul;26(4): /17

13 Aubry N, Auffray-Hillemans E, Ben Mimoun F, Brillouet N, Bugalho R, Charbon E, Oliver C, Cortinovis D, Courday P, Cserkaszky A, Damon C, Doroud K, Dressel P, Fischer JM, Fornaro G, Fourmigue JM, Frisch B, Fürst B, Gardiazabal J, Gadow K, Garutti E, Gaston C, Gil-Ortiz A, Guedj E, Harion T, Jarron P, Kabadanian J, Lasser T, Laugier R, Lecocq P, Lombardo D, Mandai S, Mas E, Meyer T, Mundler O, Nava N, Ortigão C, Paganoni M, Perrodin D, Pizzichemi M, Prior J, Reich T, Reinecke M, Rolo M, Schultz-Coulon HC, Schwaiger M, Shen W, Silenzi A, Silva JC, Silva R, Somlai Schweiger I, Stamen R, Traub J, Varela J, Veckalns V, Vidal V, Vishwas J, Wendler T, Xu C, Ziegler S and Zvolsky M. (Consortium Européen par ordre alphabétique). EndoTOFPET-US: a novel multimodal tool for endoscopy and positron emission tomography. Journal of Instrumentation (JINST) 2013, 8: C Lutz NW, Fernandez C, Pellissier JF, Cozzone PJ, Béraud E. Cerebral biochemical pathways in experimental autoimmune encephalomyelitis and adjuvant arthritis: a comparative metabolomic study. PLoS One. 2013;8(2):e Beloribi S, Ristorcelli E, Breuzard G, Silvy F, Bertrand-Michel J, Beraud E, Verine A, Lombardo D. Exosomal lipids impact notch signaling and induce death of human pancreatic tumoral SOJ-6 cells. PLoS One. 2012;7(10):e Canonici A, Pellegrino E, Siret C, Terciolo C, Czerucka D, Bastonero S, Marvaldi J, Lombardo D, Rigot V, André F. Saccharomyces boulardii improves intestinal epithelial cell restitution by inhibiting αvβ5 integrin activation state. PLoS One. 2012;7(9):e Crescence L, Beraud E, Sbarra V, Bernard JP, Lombardo D, Mas E. Targeting a novel oncoglycoprotein antigen at tumoral pancreatic cell surface by mab16d10 induces cell death. J Immunol Oct 1;189(7): Béraud E, Collignon A, Franceschi C, Olive D, Lombardo D, Mas E. Investigation of a new tumorassociated glycosylated antigen as target for dendritic cell vaccination in pancreatic cancer. Oncoimmunology Jan 1;1(1): Desmarchelier, C., Tourniaire, F., Prévéraud, D.P., Samson-Kremser, C.,Crenon, I, Rosilio, V. & Borel, P. The distribution and relative hydrolysis of tocopheryl acetate in the different matrices coexisting in the lumen of the small intestine during digestion could explain its low bioavailability, Mol Nutr Food Res. (2013) 57, Equipe 4 : * - Publications impliquant au moins 2 équipes du CRO2 Hofman V, Ilie M, Long E, Washetine K, Chabannon C, Figarella-Branger D, Clément B, Mabile L, Cambon-Thomsen A, Boucher P, Dagher G, Hewitt R, Parodi B, Hofman P. Measuring the contribution of tumor biobanks to research in oncology: surrogate indicators and bibliographic output. Biopreserv Biobank 2013, 11(4): Vasiljevic A, Champier J, Figarella-Branger D, Wierinckx A, Jouvet A, Fèvre-Montange M.Molecular characterization of central neurocytomas: potential markers for thumor typing and progression. Neuropathology 2013, 33(2) : Jaffrain Rea ML, Rotondi S, Turchi A, Occhi G, Barlier A, Peverelli E, Rostomyan L, Defilles C, Angelini M, Oliva MA, Ceccato F, Maiorani O, Daly AF, Esposito V, Buttarelli F, Figarella-Branger D, Giangaspero F, Spada A, Scaroni C, Aesse E, Beckers A. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations.endocr Relat Cancer 2013; Aug :5 : Joubert C, Dagain A, Faivre A, Nguyen AT, Fesselet J, Figarella-Branger D. Intracranial Rosai- Dorfman disease mimicking multiple meningiomas. Rev Med Brux 2013;34(2): /17

14 Tabouret E, Metellus P, Tallet A, Figarella-Branger D, Charaffe-Jauffret E, Viens P,; Gonçalves A.Clinical outcome in patients with surgiccaly resected brain metastases from breast cancer: pronostic considerations regarding molecular status and established prognostic classification systems.anticancer Res. 2013, 33(5): Bourdeaut F, Grison C, Maurage CA, laquerrière A, Vasiljevic A, Delisle MB, Michalak S, Figarella- Branger D, Doz F, Richer W, Pierron G, Miquel C, Delattre O, Couturier. MYC and MYCN amplification can be reliably assessed by acgh inmedulloblastoma.cancer Genet. 2013, 206(4): Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, Bonneville JF, Assaker R, Auger C, Brue T, Cornelius A, Dufour H, Jouanneau E, François P, Galland F, Mougel F, Chapuis F, Villeneuve L, Maurage CA, Figarella-Branger D, Raverot G; The members of HYPOPRONOS. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013; 126(1): Fernandez C, Bardin N, De Paula AM, Salort-Campana E, Benyamine A, Franques J Schleinitz N, Weiller PJ, Pouget J, Pellissier JF, Figarella-Branger D. Correlation of clinico-serologic and pathologic classifications of inflammatory myopathies: study of 178 cases and guidelines for diagnosis. Medicine (Baltimore). 2013, 92(1) :15-24 Colin C, Padovani L, Chappé C, Mercurio S, Scavarda D, Loundou A, Frassineti F, André N, Bouvier C, Korshunov A, Lena G, Figarella-Branger D. Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution. Neuropathol Appl Neurobiol. 2013, 39(6): * Ait-Belkacem R, Calligaris D, Sellami L, Villard C, Granjeaud S, Schembri T,Berenguer C, Ouafik L, Figarella-Branger D, Chinot O, Lafitte D. Tubulin isoforms identified in the brain by MALDI insource decay. J Proteomics 2013, Feb 21; 79: Chappé C, Padovani L, Scavarda D, Forest F, Nanni-Metellus I, Loundou A, Mercurio S, Fina F, Lena G, Colin C, Figarella-Branger D. Dysembryoplastic Neuroepithelial Tumours share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF(V600E) mutation and expression. Brain Pathol ; 23(5) : Fellah S, Caudal D, Maues de Paula A, Dory-Lautrec P, Figarella-Branger D, Chinot O, Metellus P, Cozzone PJ, Confort-Gouny S, Ghattas B, Callot V, Girard N. Multimodal MR imaging (diffusion, perfusion and spectroscopy): Is it possibile to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR. 2013; 34 (7): Figarella-Branger D, Chappe C, Padovani L, Mercurio S, Colin C, Forest F, Bouvier C. Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification. Bull Cancer 2013; Aug 1; 100(7-8): *Mercurio S, Padovani L, Colin C, Carré M, Tchoghandjian A, Scavarda D, Lambert S, Baeza-Kallee N, Fernandez C, Chappe C, André N, Figarella-Branger D. Evidence for new tarets and synergistic effect of metronomic celecoxib/fluvastatin combination in pilocytic astrocytoma. Acta Neuropathol commun 2013 May 20; 1(1):17 Bertucci F, Bouvier C, Finetti P, Adelaide J, Metellus P, Mokhtari K, Decouvelaere AV, Miquel C, Jouvet A, Pedeutour F, Figarella-Branger D, Chaffanet M, Birnbaum D. Comprehensive genome characterization of solitary fibrous tumors using high-resolution array-based comparative genomic hybridization.. Gene Chromos and Cancer 2013; 52(2): Tabareau-Delalande F, Collin C, Gomez-Brouchet A, Decouvelaere AV, Bouvier C, Larousserie F, Marie B, Delfour C, Aubert S, Rosset P, de Muret A, Pagès JC, depinieux G Diagnostic value of investigating GNAS mutations in fibro-osseous lesions: a retrospective study of 91 cases of fibrous dysplasia and 40 other fibro-osseous lesions. Mod Pathol Jul;26(7): Figarella-Branger D, Chappe C, Padovani L, Mercurio S, Colin C, Forest F, Bouvier C. Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification. Bull Cancer Jul-Aug;100 (7-8): /17

15 Bouvier C, Bertucci F, Métellus P, Finetti P, de Paula AM, Forest F, Mokhtari K, Miquel C, Birnbaum D, Vasiljevic A, Jouvet A, Coindre JM, Loundou A, Figarella-Branger D ALDH1 is an immunohistochemical diagnostic marker for solitary fibrous tumours and haemangiopericytomas of the meninges emerging from gene profiling study. Acta Neuropathol Commun May 9;1(1):10. Bertucci F, Bouvier C, Finetti P, Metellus P, Adelaide J, Mokhtari K, Figarella-Branger D, Decouvelaere AV, Miquel C, Coindre JM, Birnbaum D.Expression profiling of solitary fibrous tumors. Gene PLoS One May 29;8(5):e Berenguer-Daize C, Boudouresque F, Bastide C, Tounsi A, Benyahia Z, Acunzo J, Dussault N, Delfino C, Baeza-Kallee N, Cayol M, Daniel L, Rossi D, El Battari A, Bertin D, Mabrouk K Martin PM, Ouafik LH. Adrenomedullin blockade suppresses growth of human hormone independent prostate tumor xenografts in mice. Clin Cancer Res. 2013; 19: Tchoghandjian A, Jennewein C, Eckhardt I, Rajalingam K and Fulda S: Identification of noncanonical NF-jB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Cell Death Dis. 2013; Mar 28;4:e564. * Nouguerède E, Berenguer C, Garcia S, Bennani B, Delfino C, Nanni I, Dahan L, Gasmi M, Seitz J- F, Martin P-M, Ouafik L. Expression of Adrenomedullin in human colorectal tumors and its role in cell growth and invasion in vitro and in xenografts growth in vivo. Cancer Medicine. 2013; 2(2): * Serdjebi C, Seitz JF, Ciccolini J, Duluc M, Norguet E, Fina F, Lacarelle B, Ouafik L, Dahan L. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics. 2013; 14(9): Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P; MOKAECM Collaborative Group. Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience. PLoS One. 2013;8(7):e * Barlesi F, Tomasini P, Fina F, Secq V, Greillier L, Nanni-Metellus I, Garcia S, Ouafik L. Regional molecular genetics centers in thoracic oncology: what and who should be tested?. Bull Cancer. 2013;100: Plateforme SMARTc N. André, D. Barbolosi, F. Billy, G. Chapuisat, F. Hubert, E. Grenier and A. Rovini. Mathematical model of cancer growth controled by metronomic chemotherapies. ESAIM: PROCEEDINGS, 2013 Vol. 41, p Fanciullino R, Ciccolini J, Milano G. Challenges, expectations and limits for nanoparticles-based therapeutics in cancer: a focus on nano-albumin-bound drugs. Crit Rev Oncol Hematol Dec;88(3): Serdjebi C, Seitz JF, Ciccolini J, Duluc M, Norguet E, Fina F, Lacarelle B, Ouafik L, Dahan L. Rapid deaminator status is associated with poor clinical outcome in pancreatic cancer patients treated with a gemcitabine-based regimen. Pharmacogenomics Jul;14(9): doi: /pgs André F, Ciccolini J, Spano JP, Penault-Llorca F, Mounier N, Freyer G, Blay JY, Milano G. Personalized medicine in oncology: where have we come from and where are we going? Pharmacogenomics Jun;14(8): doi: /pgs Ciccolini J, Peters GJ, Giovannetti E. Gender, cytidine deaminase, and 5-aza/decitabine--letter. Clin Cancer Res Jun 1;19(11): /17

16 Milano G, Fanciullino R, Ciccolini J. Research highlights. Pharmacogenomics 2013; 14(9): Evrard A, Lacarelle B, Ciccolini J. Severe or lethal toxicities with nucleosidic analogs: time for action. Pharmacogenomics Feb;14(3): doi: /pgs No abstract available. Fanciullino R, Mollard S, Giacometti S, Berda-Haddad Y, Chefrour M, Aubert C, Iliadis A, Ciccolini J. In vitro and in vivo evaluation of lipofufol, a new triple stealth liposomal formulation of modulated 5-fu: impact on efficacy and toxicity. Pharm Res May;30(5): doi: /s Epub 2013 Feb 6. Amiot MJ, Romier B, Dao TM, Fanciullino R, Ciccolini J, Burcelin R, Pechere L, Emond C, Savouret JF, Seree E. Optimization of trans-resveratrol bioavailability for human therapy. Biochimie Jun;95(6): Carrieri MP, Lions C, Sogni P, Winnock M, Roux P, Mora M, Bonnard P, Salmon D, Dabis F, Spire B; ANRS CO13 HEPAVIH Study Group. Association between elevated coffee consumption and daily chocolate intake with normal liver enzymes in HIV-HCV infected individuals: results from the ANRS CO13 HEPAVIH cohort study. J Hepatol Jan;60(1): doi: /j.jhep Epub 2013 Aug 24. Perrin S, Cremer J, Faucher O, Reynes J, Dellamonica P, Micallef J, Solas C, Lacarelle B, Stretti C, Kaspi E, Robaglia-Schlupp A, Tamalet CN, Lévy N, Poizot-Martin I, Cau P, Roll P. Correction: HIV Protease Inhibitors Do Not Cause the Accumulation of Prelamin A in PBMCs from Patients Receiving First Line Therapy: The ANRS EP45 "Aging" Study. PLoS One Aug 14;8(8). Colson P, Bregigeon S, Tourres C, Solas C, Poizot-Martin I, Tamalet C. Relapse of hepatitis C virus after 14 months of sustained virological response following pegylated-interferon alpha plus ribavirin therapy in a human immunodeficiency virus type 1 infected patient. J Clin Virol Sep;58(1): Hajji H, Gérolami R, Solas C, Moreau J, Colson P. Chronic hepatitis E resolution in a human immunodeficiency virus (HIV)-infected patient treated with ribavirin. Int J Antimicrob Agents Jun;41(6): doi: /j.ijantimicag Marcellin F, Lions C, Winnock M, Salmon D, Durant J, Spire B, Mora M, Loko MA, Dabis F, Dominguez S, Roux P, Carrieri MP; ANRS CO13 HEPAVIH Study Group. Self-reported alcohol abuse in HIV-HCV co-infected patients: a better predictor of HIV virological rebound than physician's perceptions (HEPAVIH ARNS CO13 cohort). Addiction Jul;108(7): Poizot-Martin I, Solas C, Allemand J, Obry-Roguet V, Pradel V, Bregigeon S, Faucher O, Lacarelle B. Renal impairment in patients receiving a tenofovir-cart regimen: impact of tenofovir trough concentration. J Acquir Immune Defic Syndr Apr 1;62(4): Faivre C, Barbolosi D, Pasquier E, André N. A mathematical model for the administration of temozolomide: comparative analysis of conventional and metronomic chemotherapy regimens. Cancer Chemother Pharmacol Apr;71(4): Ciccolini J, Fanciullino R, Milano G. Predicting survival of gastric cancer patients treated with 5- fluorouracil-based regimen: falling again on TP53 Pharmacogenomics 2013; 14(10): D. Barbolosi A. Benabdallah S. Benzekry J. Ciccolini C. Faivre F. Hubert F. Verga B. You A Mathematical Model for Growing Metastases on Oncologists s Service. In book: Computational Surgery and Dual Training, Publisher: SPRINGER, Editors: Garbey, M, Bass, B.L., Collet, C, Mathelin, M, Tran-Son-Tay, R. Eds, pp Plateforme PIT2. Salmi M, Bruneau N, Cillario J, Lozovaya N, Massacrier A, Buhler E, Cloarec R, Tsintsadze T, Watrin F, Tsintsadze V, Zimmer C, Villard C, Lafitte D, Cardoso C, Bao L, Lesca G, Rudolf G, Muscatelli F, Pauly V, Khalilov I, Durbec P, Ben-Ari Y, Burnashev N, Represa A, Szepetowski P. Tubacin prevents neuronal migration defects and epileptic activity caused by rat Srpx2 silencing in utero. Brain Aug;136(Pt 8): /17

17 Stalin J, Harhouri K, Hubert L, Subrini C, Lafitte D, Lissitzky JC, Elganfoud N, Robert S, Foucault-Bertaud A, Kaspi E, Sabatier F, Aurrand-Lions M, Bardin N, Holmgren L, Dignat-George F, Blot-Chabaud M. Soluble melanoma cell adhesion molecule (smcam/scd146) promotes angiogenic effects on endothelial progenitor cells through angiomotin. J Biol Chem Mar 29;288(13): Ait-Belkacem R, Calligaris D, Sellami L, Villard C, Granjeaud S, Schembri T, Berenguer C, Ouafik L, Figarella-Branger D, Chinot O, Lafitte D. Tubulin isoforms identified in the brain by MALDI in-source decay. J Proteomics Feb 21;79: /17